Render Target: SSR
Render Timestamp: 2024-11-01T00:40:00.810Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-09-20 06:21:27.016
Product last modified at: 2024-09-13T07:01:43.078Z
1% for the planet logo
PDP - Template Name: IHC Kit
PDP - Template ID: *******35f95d7

Growth/Proliferation Marker: SignalStain® Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) IHC Detection Kit #8110

Inquiry Info. # 8110

Please see our recommended alternatives.

    Product Information

    Product Description

    CST's Growth/Proliferation Marker: SignalStain® Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Detection Kit is a "ready to use" system designed to detect the activation of MAP kinase in human tissue and cell preps by immunohistochemistry. The kit utilizes the ABC immunoperoxidase method to detect endogenous levels of phosphorylated p44/42 MAP kinase. Prediluted Phospho-p44/42MAPK (Thr202/Tyr204) (20G11) Rabbit mAb #4376 is bound by a biotinylated secondary antibody. Avidin DH and biotinylated horseradish peroxidase are complexed by mixing in defined amounts prior to use, and the mixture subsequently binds the secondary antibody. The macromolecular complex is localized by incubation with NovaRED™ enzyme substrate.
    The prediluted primary antibody, along with the ABC system, allows the user consistently to examine phosphorylated-p44/42 MAP Kinase localization and offers the highest sensitivity with the lowest background.

    Specificity / Sensitivity

    Growth/Proliferation Marker: SignalStain® Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Detection Kit recognizes endogenous levels of p42 and p44 MAP kinase (Erk1 and Erk2) only when phosphorylated at Thr202 and Tyr204 of Erk1 (Thr183 and Tyr185 of Erk2). The antibody does not cross-react with the corresponding phosphorylated residues of either SAPK/JNK or p38 MAP kinase. This kit was developed for and is recommended for immunohistochemistry only.

    The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.

    Species predicted to react based on 100% sequence homology:

    Mouse, Rat, Monkey, Zebrafish

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr202/Tyr204 of human p44 MAP kinase.

    Background

    Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli, including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.